We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
VERY LONG‐TERM FOLLOW‐UP OF RITUXIMAB MAINTENANCE IN YOUNG PATIENTS WITH MANTLE CELL LYMPHOMA INCLUDED IN THE LYMA TRIAL, A LYSA STUDY.
- Authors
Sarkozy, C.; Thieblemont, C.; Oberic, L.; Moreau, A.; Bouabdallah, K.; Damaj, G.; Gastine, T.; Ribrag, V.; Casasnovas, O.; Haioun, C.; Houot, R.; Jardin, F.; Van Den Neste, E.; Cheminant, M.; Morschhauser, F.; Callana, M.; Ghesquieres, H.; Gressin, R.; Hermine, O.; Le Gouill, S.
- Abstract
In the RM arm, 22 patients had died (18.3%) versus 33 (27.5%) in the observation arm with a 7-year OS estimate of 83.2% (95% CI: 74.7.7%-89.0%) and 72.2% (95% CI 62.9%-79.5%) in RM and observation arm, respectively ( I p i = 0.087). B Aim: b the phase III LYMA trial demonstrated the efficacy (OS, PFS, EFS) and safety of rituximab maintenance (RM) post autologous stem cell transplant (ASCT) in first line for young patients with mantle cell lymphoma (MCL) (Le Gouill et al., NEJM). VERY LONG-TERM FOLLOW-UP OF RITUXIMAB MAINTENANCE IN YOUNG PATIENTS WITH MANTLE CELL LYMPHOMA INCLUDED IN THE LYMA TRIAL, A LYSA STUDY.
- Subjects
MANTLE cell lymphoma; RITUXIMAB; CLINICAL trials
- Publication
Hematological Oncology, 2023, Vol 41, p151
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3163_100